Cargando…

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination

OBJECTIVE: We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination. METHODS: We evaluated clinical phenotypes, annualised relapse rates (ARR) prior and on immunotherapy and Expanded Disabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramanathan, Sudarshini, Mohammad, Shekeeb, Tantsis, Esther, Nguyen, Tina Kim, Merheb, Vera, Fung, Victor S C, White, Owen Bruce, Broadley, Simon, Lechner-Scott, Jeannette, Vucic, Steve, Henderson, Andrew P D, Barnett, Michael Harry, Reddel, Stephen W, Brilot, Fabienne, Dale, Russell C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Neuro-Inflammation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800335/ https://www.ncbi.nlm.nih.gov/pubmed/29142145 http://dx.doi.org/10.1136/jnnp-2017-316880

Ejemplares similares

Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton
por: Dale, Russell C., et al.
Publicado: (2014)

B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination
por: Kothur, Kavitha, et al.
Publicado: (2016)

Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
por: Mathey, Emily K, et al.
Publicado: (2015)

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
por: Tea, Fiona, et al.
Publicado: (2019)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders
por: Rinaldi, Simon, et al.
Publicado: (2020)

Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry
por: Tea, Fiona, et al.
Publicado: (2020)

Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
por: Seneviratne, Sinali O., et al.
Publicado: (2022)

Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes
por: Vu, Lucas, et al.
Publicado: (2020)

Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias
por: King, Eleanor, et al.
Publicado: (2018)

Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease
por: Lopez, Joseph A, et al.
Publicado: (2021)

Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management
por: Abboud, Hesham, et al.
Publicado: (2021)

Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management
por: Abboud, Hesham, et al.
Publicado: (2021)

Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens
por: Hacohen, Yael, et al.
Publicado: (2013)

Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre
por: Paterson, Ross W, et al.
Publicado: (2013)

Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease
por: Rossi, Meghan, et al.
Publicado: (2015)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
por: Waters, Patrick, et al.
Publicado: (2016)

Autologous haematopoietic stem cell transplantation for neurological diseases
por: Burman, Joachim, et al.
Publicado: (2018)

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
por: Binks, Sophie N M, et al.
Publicado: (2018)

Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies
por: Lang, Bethan, et al.
Publicado: (2017)

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
por: Stellmann, Jan-Patrick, et al.
Publicado: (2017)

Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer’s disease: an observational clinical study
por: Amin, Jay, et al.
Publicado: (2020)

Neuroinflammation predicts disease progression in progressive supranuclear palsy
por: Malpetti, Maura, et al.
Publicado: (2021)

Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies
por: McGinty, Ronan N, et al.
Publicado: (2021)

Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
por: Lu, Angelo, et al.
Publicado: (2022)

LGI1 antibody encephalitis: acute treatment comparisons and outcome
por: Rodriguez, Andrew, et al.
Publicado: (2022)

Clinical spectrum of high-titre GAD65 antibodies
por: Budhram, Adrian, et al.
Publicado: (2021)

TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
por: Hilezian, Frédéric, et al.
Publicado: (2021)

In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer’s disease
por: Low, Audrey, et al.
Publicado: (2021)

Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors
por: Wang, Liang, et al.
Publicado: (2021)

Association of obesity with disease outcome in multiple sclerosis
por: Lutfullin, Isabel, et al.
Publicado: (2023)

Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders
por: Oertel, Frederike Cosima, et al.
Publicado: (2023)

Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis
por: Leppert, David, et al.
Publicado: (2023)

Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders
por: Sinmaz, Nese, et al.
Publicado: (2016)

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis
por: Ramanathan, Sudarshini, et al.
Publicado: (2014)

Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis
por: Kothur, Kavitha, et al.
Publicado: (2016)

Humoral signatures of MOG-antibody-associated disease track with age and disease activity
por: Spatola, Marianna, et al.
Publicado: (2023)

International multicenter examination of MOG antibody assays
por: Reindl, Markus, et al.
Publicado: (2020)

Multiple hypertrophic relapsing remitting cranial neuropathies as an initial presentation of primary CNS lymphoma without any brain or spinal cord lesion
por: Watane, Gaurav V, et al.
Publicado: (2016)

Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases
por: Schanda, Kathrin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r80kbfjgnkljfp14n31ei7la3q